Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 21

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 21
---
 of the Nominating and Corporate Governance Committee in July 2024. |

| (2) | Ms. Oliger was appointed as a member of the Nominating and Corporate Governance Committee in June 2024. |

Each of the committees has authority to engage legal counsel or other experts or consultants, as it deems appropriate to carry out its responsibilities. The Board has determined that each member of each committee meets the applicable Nasdaq rules and regulations regarding “independence” and each member is free of any relationship that would impair his or her individual exercise of independent judgment with regard to the Company. Below is a description of each committee of the Board. Audit Committee The Audit Committee was established by the Board in accordance with Section 3(a)(58)(A) of the Exchange Act, to oversee the Company’s corporate accounting and financial reporting processes and audits of its financial statements. The primary purpose of the Audit Committee is to discharge the responsibilities of the Board with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered accounting firm. Specific responsibilities of the Audit Committee include:

| • | helping the Board oversee our corporate accounting and financial reporting processes; |

| • | managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements; |

| • | discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results; |

| • | developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; |

| • | monitoring and assessing, and overseeing the reporting of, any material cybersecurity breaches and associated risks; |

| • | reviewing related person transactions; |

| • | obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our internal quality control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and |

| • | approving, or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm. |

12

TABLE OF CONTENTS The Audit Committee is composed of three directors: Mr. Morrison, Dr. Morrissey, and Dr. Seidenberg. The Audit Committee met four times during 2024. The Board has adopted a written Audit Committee charter that is available to stockholders on